Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649)

被引：0
|
作者：
Lin, Daniel
Quan, Wenying
Garretson, Marne
Chirikov, Viktor
Chen, Clara
Singh, Prianka
Davis, Catherine
Sugarman, Ryan
机构：
[1] Thomas Jefferson Univ Hosp, Philadelphia, PA USA
[2] OPEN Hlth, Bethesda, MD USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4044
引用
收藏
页数：1
相关论文
共 38 条
  • [31] Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) versus chemo (C)
    Moehler, M.
    Wyrwicz, L.
    Chen, C.
    Davenport, E.
    Wang, J.
    Nathani, R.
    Kondo, K.
    Elimova, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S185 - S185
  • [32] Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) vs (C)
    Moehler, Markus
    Wyrwicz, Lucjan
    Chen, Clara
    Davenport, Eric
    Wang, Jinyi
    Nathani, Raheel
    Kondo, Kaoru
    Elimova, Elena
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 65 - 65
  • [33] Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
    Jiang, Yuan
    Li, Yue
    Wang, Larry X. W.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (02) : 499 - 506
  • [34] Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
    Yuan Jiang
    Yue Li
    Larry X. W. Wang
    International Journal of Clinical Pharmacy, 2022, 44 : 499 - 506
  • [35] A quality-adjusted time without symptoms and toxicity (Q-TWiST) analysis comparing nivolumab plus ipilimumab (N plus I) or nivolumab plus chemotherapy (N plus CT) versus CT in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648.
    Chau, Ian
    Bridgewater, John A.
    Wyrwicz, Lucjan
    Greenwood, Mike
    Blum, Steven I.
    Moreno-Koehler, Alejandro
    Worthy, Gill
    Taylor, Fiona
    Davis, Catherine
    Chen, Clara
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 251 - 251
  • [36] A Quality-adjusted Time Without Symptoms and Toxicity (Q-TWiST) analysis comparing nivolumab plus chemotherapy (N plus CT) or nivolumab plus ipilimumab (N plus I) vs CT in patients (pts) with tumor cell PD-L1 ≥ 1% advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648
    Chau, I.
    Bridgewater, J. A.
    Wyrwicz, L. S.
    Greenwood, M.
    Blum, S. I.
    Moreno-Koehler, A.
    Martin, E.
    Taylor, F.
    Davis, C.
    Singh, P.
    ANNALS OF ONCOLOGY, 2024, 35 : S162 - S162
  • [37] Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.
    Paz-Ares, Luis G.
    Ciuleanu, Tudor-Eliade
    Lee, Jong-Seok
    Urban, Laszlo
    Caro, Reyes Bernabe
    Park, Keunchil
    Sakai, Hiroshi
    Ohe, Yuichiro
    Nishio, Makoto
    Pluzanski, Adam
    Ramalingam, Suresh S.
    Brahmer, Julie R.
    Borghaei, Hossein
    O'Byrne, Kenneth John
    Hellmann, Matthew D.
    Memaj, Arteid
    Bushong, Judith
    Tran, Phuong
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227
    Schumann, C.
    Paz-Ares, L.
    Ciuleanu, T. -E
    Lee, J. -S
    Urban, L.
    Caro, Bernabe R.
    Park, K.
    Sakai, H.
    Ohe, Y.
    Nishio, M.
    Pluzanski, A.
    Ramalingam, S. S.
    Brahmer, J. R.
    Borghaei, H.
    O'Byrne, K. J.
    Hellmann, M. D.
    Memaj, A.
    Bushong, J.
    Tran, P.
    Reck, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 173 - 173
1234